C Dufton
Overview
Explore the profile of C Dufton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spence R, Mandagere A, Richards D, Magee M, Dufton C, Boinpally R
Clin Pharmacol Ther
. 2010 Sep;
88(4):513-20.
PMID: 20811346
Ambrisentan (ABS), approved for the treatment of pulmonary arterial hypertension and administered as an oral dose once daily, is an ET(A)-selective endothelin receptor antagonist (ERA) and a potential substrate for...
2.
Carl T, Dufton C, Hanken J, Klymkowsky M
Dev Biol
. 1999 Aug;
213(1):101-15.
PMID: 10452849
Based primarily on studies in the chick, it has been assumed that the zinc finger transcription factor Slug is required for neural crest migration. In the mouse, however, Slug is...
3.
Stemmer S, Cagnoni P, Shpall E, Bearman S, Matthes S, Dufton C, et al.
J Clin Oncol
. 1996 May;
14(5):1463-72.
PMID: 8622060
Purpose: To determine the maximal-tolerated dose (MTD) of paclitaxel in combination with high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous hematopoietic progenitor-cell support (AHPCS). Patients And Methods: Forty-nine patients...
4.
Schrier D, Stemmer S, Johnson T, KASLIWAL R, Lear J, Matthes S, et al.
Cancer Res
. 1995 Dec;
55(23 Suppl):5921s-5924s.
PMID: 7493371
This Phase I trial explores the use of high-dose 90Y conjugated to the antibreast cancer monoclonal antibody BrE-3 and autologous hematologic cell support in the treatment of women with stage...
5.
Jones R, Matthes S, Kemme D, Dufton C, Kernan S
Cancer Chemother Pharmacol
. 1994 Jan;
35(1):59-63.
PMID: 7987978
Cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) constitute a combination alkylating-agent regimen commonly used with autologous marrow support. Its therapeutic effectiveness is accompanied by sporadic life-threatening and fatal toxicities, the most common...
6.
Jones R, Matthes S, Shpall E, Fisher J, Stemmer S, Dufton C, et al.
J Natl Cancer Inst
. 1993 Apr;
85(8):640-7.
PMID: 8468721
Background: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who...
7.
Jones R, Matthes S, Dufton C, Bearman S, Stemmer S, Meyers S, et al.
Breast Cancer Res Treat
. 1993 Jan;
26 Suppl:S11-7.
PMID: 8400329
Combinations of alkylating agents in intensive doses with autologous hematopoietic cell support (AHCS) are commonly used to treat advanced, solid tumors. Relatively little is known about the pharmacokinetic or pharmacodynamic...